Owen McCarty is an American biomedical engineer who studies the dynamics of the vascular system in the context of cancer metastasis, cardiovascular disease, and inflammation. He is the Douglas Strain Professor and Chair of the Biomedical Engineering Department at Oregon Health & Science University (OHSU) and a fellow of the American Heart Association.[1]

Owen McCarty
Alma materUniversity of Buffalo
Johns Hopkins University
Websitehttps://www.ohsu.edu/people/owen-jt-mccarty-phd-faha

Education and career edit

McCarty received his B.S. in Chemical Engineering from SUNY-Buffalo. He attended Johns Hopkins University to pursue his Ph.D. with Konstantinos Konstantopoulos and investigate tumor cell receptors for white blood cells and platelets.[2] He completed his post-doctoral training under the mentorship of Steve Watson as a Wellcome Trust Fellow in the Pharmacology Department at the University of Oxford and University of Birmingham. In 2005, he accepted a faculty position in the Department of Biomedical Engineering at Oregon Health & Science University. He has served as chair of the Biomedical Engineering Department since 2019 and orchestrated collaborative partnerships with OHSU's School of Medicine, School of Dentistry, and external institutions.

Current work and achievements edit

McCarty investigates fluid mechanics and cellular biology of the vasculature with the goal of translating these insights into molecular-targeted therapies. His research program has helped take two drug candidates to clinical trials and has also provided insight on the anti-cancer effects of aspirin.[3][4][5]

Honors and awards edit

Publications edit

  • McCarty, O. J., Mousa, S. A., Bray, P. F., & Konstantopoulos, K. (2000). Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood, The Journal of the American Society of Hematology, 96(5), 1789-1797.[6]
  • McCarty, O. J., Larson, M. K., Auger, J. M., Kalia, N., Atkinson, B. T., Pearce, A. C., ... & Watson, S. P. (2005). Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. Journal of biological chemistry, 280(47), 39474-39484.[7]
  • Cheng, Q., Tucker, E. I., Pine, M. S., Sisler, I., Matafonov, A., Sun, M. F., ... McCarty, O. J. T., ... & Gailani, D. (2010). A role for factor XIIa–mediated factor XI activation in thrombus formation in vivo. Blood, The Journal of the American Society of Hematology, 116(19), 3981-3989.[8]
  • Aslan, J. E., & McCarty, O. J. (2013). Rho GTPases in platelet function. Journal of Thrombosis and Haemostasis, 11(1), 35-46.[9]
  • Itakura, A., & McCarty, O. J. (2013). Pivotal role for the mTOR pathway in the formation of neutrophil extracellular traps via regulation of autophagy. American Journal of Physiology. Cell Physiology, 305(3), C348-C354.[10]

References edit

  1. ^ "Owen McCarty". Retrieved 2022-02-08.
  2. ^ McCarty, O.; Konstantopoulos, K. (October 1999). "Molecular mechanisms of platelet-tumor cell adhesion under flow". Proceedings of the First Joint BMES/EMBS Conference. 1999 IEEE Engineering in Medicine and Biology 21st Annual Conference and the 1999 Annual Fall Meeting of the Biomedical Engineering Society (Cat. No.99CH37015). Vol. 1. pp. 61 vol.1–. doi:10.1109/IEMBS.1999.802096. ISBN 0-7803-5674-8. S2CID 86118001.
  3. ^ "New study explains how low-dose aspirin may prevent cancer". www.medicalnewstoday.com. 2016-12-24. Retrieved 2022-02-08.
  4. ^ Mitrugno, Annachiara; Sylman, Joanna L.; Ngo, Anh T. P.; Pang, Jiaqing; Sears, Rosalie C.; Williams, Craig D.; McCarty, Owen J. T. (2017-02-01). "Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC". American Journal of Physiology. Cell Physiology. 312 (2): C176–C189. doi:10.1152/ajpcell.00196.2016. ISSN 0363-6143. PMC 5336594. PMID 27903583.
  5. ^ Lorentz, Christina U.; Verbout, Norah G.; Wallisch, Michael; Hagen, Matthew W.; Shatzel, Joseph J.; Olson, Sven R.; Puy, Cristina; Hinds, Monica T.; McCarty, Owen J.T.; Gailani, David; Gruber, András; Tucker, Erik I. (2019-04-01). "Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial". Arteriosclerosis, Thrombosis, and Vascular Biology. 39 (4): 799–809. doi:10.1161/ATVBAHA.118.312328. PMC 6494446. PMID 30700130.
  6. ^ McCarty, Owen J. T.; Mousa, Shaker A.; Bray, Paul F.; Konstantopoulos, Konstantinos (2000-09-01). "Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions". Blood. 96 (5): 1789–1797. doi:10.1182/blood.V96.5.1789. ISSN 0006-4971. PMID 10961878.
  7. ^ McCarty, Owen J. T.; Larson, Mark K.; Auger, Jocelyn M.; Kalia, Neena; Atkinson, Ben T.; Pearce, Andrew C.; Ruf, Sandra; Henderson, Robert B.; Tybulewicz, Victor L. J.; Machesky, Laura M.; Watson, Steve P. (2005-11-25). "Rac1 Is Essential for Platelet Lamellipodia Formation and Aggregate Stability under Flow *". Journal of Biological Chemistry. 280 (47): 39474–39484. doi:10.1074/jbc.M504672200. ISSN 0021-9258. PMC 1395485. PMID 16195235.
  8. ^ Cheng, Qiufang; Tucker, Erik I.; Pine, Meghann S.; Sisler, India; Matafonov, Anton; Sun, Mao-fu; White-Adams, Tara C.; Smith, Stephanie A.; Hanson, Stephen R.; McCarty, Owen J. T.; Renné, Thomas (2010-11-11). "A role for factor XIIa–mediated factor XI activation in thrombus formation in vivo". Blood. 116 (19): 3981–3989. doi:10.1182/blood-2010-02-270918. ISSN 0006-4971. PMC 2981546. PMID 20634381.
  9. ^ Aslan, J. E.; Mccarty, O. J. T. (2013). "Rho GTPases in platelet function". Journal of Thrombosis and Haemostasis. 11 (1): 35–46. doi:10.1111/jth.12051. ISSN 1538-7836. PMC 3928789. PMID 23121917.
  10. ^ Itakura, Asako; McCarty, Owen J. T. (2013-08-01). "Pivotal role for the mTOR pathway in the formation of neutrophil extracellular traps via regulation of autophagy". American Journal of Physiology. Cell Physiology. 305 (3): C348–C354. doi:10.1152/ajpcell.00108.2013. ISSN 0363-6143. PMC 3742850. PMID 23720022.